Hormone replacement therapy, previous breast surgery, and a low body mass index may reduce the accuracy of screening mammography, according to a study in the August issue of the British Medical Journal.
Hormone replacement therapy, previous breast surgery, and a low body mass index may reduce the accuracy of screening mammography, according to a study in the August issue of the British Medical Journal.
Age, family history, physical activity levels, smoking, and alcohol consumption did not significantly affect the exam's sensitivity or specificity.
Dr. Emily Banks, deputy director of the cancer research U.K. epidemiology unit at the University of Oxford, and colleagues studied 122,355 women from 50 to 64 years of age. The participants in the U.K.'s Million Women Study had all completed a lifestyle questionnaire and were monitored for 12 months.
The researchers reported an overall sensitivity of 86.6% and specificity of 96.8% for the diagnosis of breast cancer in 726 women.
The following factors had an adverse affect on both sensitivity and specificity:
Women who have these confounding factors also are more likely than other women to have breast cancer diagnosed between screens, Banks said.
While study results indicate that some women may be at a disadvantage in terms of screening mammogram accuracy, the researchers cautioned that it is still the best way to find early stage breast cancers.
They highlighted their results as indicative of the importance of routine screening and of women remaining vigilant between screenings.
For more from the online Diagnostic Imaging archives:
False-positive rate for screening mammography drops
Yearly mammograms prove insufficient for BRCA carriers
MR spectroscopy adds specificity to breast MR
Dutch researchers dismiss HRT link to breast density
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.